3.45

1.15% -0.04

After Hours: 3.41 -0.04 -1.16%

Genfit ADR (GNFT)

Overview News Price History Discussions Forecast

Genfit ADR stock is currently priced at $3.45, with a 24-hour trading volume of 12,609. It has seen a -1.15% decreased in the last 24 hours and a -6.12% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.48 pivot point. If it approaches the $3.41 support level, significant changes may occur.

Previous Close:

$3.49

Open:

$3.42

24h Volume:

12,609

Market Cap:

$172.02M

Revenue:

Net Income/Loss:

P/E Ratio:

-4.6996

EPS:

-0.7341

Net Cash Flow:

1W Performance:

-3.90%

1M Performance:

-6.12%

6M Performance:

+16.16%

1Y Performance:

-7.75%

1D Range:

$3.40

$3.5586

52W Range:

$2.8935

$4.75

Genfit ADR Stock (GNFT) Company Profile

Name

Genfit ADR

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

33 3 20 16 40 00

Address

Parc Eurasanté, 885, Avenue Eugène Avinée, Loos

Employee

148

Twitter

@genfit_pharma

Next Earnings Date

Latest SEC Filings

GNFT's Discussions on Twitter

Genfit ADR Stock (GNFT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-21	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-23-20	Upgrade	Stifel	Hold → Buy
Jun-25-20	Initiated	BofA/Merrill	Underperform
May-13-20	Downgrade	Kepler	Buy → Reduce
May-12-20	Downgrade	Barclays	Overweight → Equal Weight
May-12-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-29-19	Reiterated	B. Riley FBR	Buy
Jun-25-19	Initiated	Stifel	Hold
Apr-24-19	Initiated	SVB Leerink	Outperform
Apr-22-19	Initiated	Barclays	Overweight

View All

Genfit ADR Stock (GNFT) Latest News

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

GlobeNewswire Inc.

GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires

GlobeNewswire Inc.

GENFIT : Mise à disposition du Document d’Enregistrement Universel 2023 et du Rapport Annuel Form 20-F 2023

GlobeNewswire Inc.

Genfit ADR Stock (GNFT) Financials Data

There is no financial data for Genfit ADR (GNFT). Check out other stocks for more information.

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.